Patch testing is a vital component of the workup for allergic contact dermatitis. There are limited data on changes of patch testing use among Medicare providers, as well as patch testing reimbursement rates.
Objective
The aim of the study was to evaluate trends in the use of patch testing among various Medicare providers and Medicare patch testing reimbursement.
Design
A longitudinal analysis of patch testing claims was performed with the Medicare Part B Physician/Supplier Procedure Summary files from 2010 to 2018. The primary outcomes were the total number and change in the number of submitted patch testing services from 2010 to 2018 by 3 provider groups: dermatology physicians, nondermatology physicians, and nonphysician providers. Secondary outcome measures included Medicare reimbursement amounts and changes in reimbursement amounts for patch test services (total and per 1000 enrollees) from 2010 to 2018 for the 3 provider groups, as well as per patch test service.
Results
From 2010 to 2018, submitted patch testing services per 1000 enrollees grew by 89.0%. The annual trend estimate for submitted services relative to 2010 was +10.1% (95% confidence interval [CI] = 8.1 to 12.0) for physicians and +34.1% (95% CI = 32.1 to 36.0) for nonphysician providers (physician assistants and nurse practitioners). Among physicians, the annual trend estimate for submitted services was +5.1% (95% CI = −11.3 to 21.5) for dermatologists and +31.40% (95% CI = 15.00 to 47.81) for allergists.
Conclusions
Patch testing increased in the US Medicare population from 2010 to 2018, and this increase was largely driven by nonphysician providers and allergists.
Get full access to this article
View all access options for this article.
References
1.
AlinaghiF, BennikeNH, EgebergA, et al.Prevalence of contact allergy in the general population: a systematic review and meta-analysis. Contact Dermatitis, 2019; 80(2):77–85.
2.
MowadCM, AndersonB, ScheinmanP, et al.Allergic contact dermatitis: patient diagnosis and evaluation. J Am Acad Dermatol, 2016; 74(6):1029–1040.
3.
KrobHA, FleischerABJr., D'AgostinoRJr., et al. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of publishedT.R.U.E. test data. J Am Acad Dermatol, 2004; 51(3):349–353.
4.
CheraghlouS, WatskyKL, CohenJM. Utilization, cost, and provider trends in patch testing among Medicare beneficiaries in the United States from 2012 to 2017. J Am Acad Dermatol, 2020; S0190-9622(20):30793.
RosenkrantzAB, HughesDR, DuszakR Jr. Medicare claims data resources: a primer for policy-focused radiology health services researchers. J Am Coll Radiol, 2017; 14(12):1538–1544.
7.
YeungH, BaranowskiML, SwerlickRA, et al.Use and cost of actinic keratosis destruction in the Medicare Part B fee-for-service population, 2007 to 2015. JAMA Dermatol, 2018; 154(11):1281–1285.
8.
RogersHW, WeinstockMA, FeldmanSR, et al.Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol, 2015; 151(10):1081–1086.
9.
WeinsteinDA, KondaS, ColdironBM. Use of skin biopsies among dermatologists. Dermatol Surg, 2017; 43(11):1348–1357.
10.
VidyasagarK.Assessment of the growth of epidural injections in the Medicare population from 2000 to 2011. Pain Physician, 2013; 16:E349–E364.
11.
DodooMS, DuszakRJr., HughesDR. Trends in the utilization of medical imaging from 2003 to 2011: clinical encounters offer a complementary patient-centered focus. J Am Coll Radiol, 2013; 10(7):507–512.
HamannD, ZhangM, TaylorJ. Medicare patch test billing data by dermatologists and allergists from 2012–2016. Am Contact Dermatitis Soc, 2019; 30(3):e1–e13.
21.
EhrlichA, KosteckiJ, OlkabaH. Trends in dermatology practices and the implications for the workforce. J Am Acad Dermatol, 2017; 77(4):746–752.
22.
ZhuTH, SureshR, FarahnikB, et al.Survey of patch test business models in the United States by the American Contact Dermatitis Society. Dermatitis, 2018; 29(2):85–88.
23.
JamesWD, RosenthalLE, BrancaccioRR, et al.American Academy of Dermatology Patch Testing Survey: use and effectiveness of this procedure. J Am Acad Dermatol, 1992; 26(6):991–994.
24.
PorterML, KimballAB. Predictions, surprises, and the future of the dermatology workforce. JAMA Dermatol, 2018; 154(11):1253–1255.
25.
FengH, Berk-KraussJ, FengPW, et al.Comparison of dermatologist density between urban and rural counties in the United States. JAMA Dermatol, 2018; 154(11):1265–1271.
26.
GlazerAM, HolyoakK, CheeverE, et al.Analysis of US dermatology physician assistant density. J Am Acad Dermatol, 2017; 76(6):1200–1202.
27.
AndersonAM, MatsumotoM, SaulMI, et al.Accuracy of skin cancer diagnosis by physician assistants compared with dermatologists in a large health care system. JAMA Dermatol, 2018; 154(5):569–573.
28.
SchleichertRA, HostetlerSG, ZirwasMJ. Patch testing practices of American Contact Dermatitis Society members. Dermatitis, 2010; 21(2):98–101.
The American Board of Allergy & Immunology. Procedure skills assessment form. Available at: https://www.abai.org/ProcSkills.asp. Accessed December1, 2019.
31.
CharlesworthEN.The allergy and immunology specialist: what is the role in the treatment of skin disease?. Clin Rev Allergy Immunol, 2004; 27(2):123–132.
32.
Centers for Medicare & Medicaid Services. Medicare program; revisions to payment policies under the physician fee schedule, clinical laboratory fee schedule, access to identifiable data for the Center for Medicare and Medicaid Innovation Models & other revisions to Part B for CY 2015. Final rule with comment period. Fed Regist, 2014; 79(219):67547–68010.
33.
SpikerA, MowadCM. Evaluation and management of patch test-negative patients with generalized dermatitis. Dermatitis, 2017; 28(4):261–264.
34.
SchalockPC, DunnickCA, NedorostS, et al.American Contact Dermatitis Society Core Allergen Series. Dermatitis, 2013; 24(1):7–9.
35.
US Food and Drug Administration. BLA clinical review memorandum: Thin-layer Rapid Use Epicutaneous patch test. 2020. Available at: https://www.fda.gov/media/107666/download. Accessed March26, 2020.
36.
YaJ, EzaldeinHH, ScottJF. Trends in Medicare utilization by dermatologists, 2012–2015. JAMA Dermatol, 2019; 155(4):471–474.
